Announcement PDF ASX Announcement MAYNE PHARMA BIOSHARES SUMMIT PRESENTATION 5 August 2026, Adelaide, Australia: Mayne Pharma Group Limited (Mayne Pharma or the Company) (ASX: MYX), today provides the presentation to be given by the Company’s CEO Mr Aaron Gray to the 20th Bioshares Summit in Queenstown, New Zealand at 9.40am (NZ time) on Thursday 6 August 2026. A copy of the presentation is attached. For further information contact: Dr Tom Duthy Investor Relations +61 402 493 727 ir@maynepharma.com Authorised for release to the ASX by the Chair. Email Alerts To register for an email alert service to receive Mayne Pharma announcements released to the Australian Securities Exchange (ASX) please visit https://www.maynepharma.com/investor- relations/email-alerts/ Follow us on LinkedIn About Mayne Pharma Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne Pharma is a leader in dermatology and women’s health in the United States and also provides contract development and manufacturing services to clients worldwide. Mayne Pharma has a 40- year track record of innovation and success in developing new oral drug delivery systems. These technologies have been successfully commercialised in numerous products that continue to be marketed around theworld. Tolearn more about MaynePharma, pleasevisit maynepharma.com. Mayne Pharma Group Limited 20th Bioshares Summit Aaron Gray CEO 6 August 2026 2 Disclaimer The information provided is general in nature and is in summary form only. It is not complete and should be read in conjunction with the company’s audited Financial Statements and market disclosures. This material is not intended to be relied upon as advice to investors or potential investors. Non-IFRS information ● Other than as indicated, the financial information contained in this document is directly extracted or calculated from the audited Financial Statements. Throughout this document some non-IFRS financial information is stated, excluding certain specified income and expenses. Results excluding such items are considered by the Directors to provide a meaningful basis for comparison from period to period. ● Earnings before interest, tax, impairment, depreciation and amortisation (EBITDA) – a non-IFRS term – is considered by Directors to be a meaningful measure of the operating earnings and performance of the Group and this information may be useful for investors as it provides additional and relevant information that reflects the underlying performance of the business. ● The non-IFRS financial information has not been audited by the Group’s auditors. Forward looking statements ● This presentation contains forward-looking statements that involve subjective judgement and analysis and are subject to significant uncertainties, risks and contingencies, many of which are outside the control of, and are unknown to the Company. These forward looking statements use words such as ‘potential’, ‘expect’, ‘anticipate’, ‘intend’, ‘plan’ and ‘may’, and other words of similar meaning. No representation, warranty or assurance (express or implied) is given or made in relation to any forward looking statement by any person (including the Company). Actual future events may vary materially from the forward looking statements and the assumptions on which the forward looking statements are based. Given these uncertainties, readers are cautioned not to place undue reliance on such forward looking statements. Subject to the Company’s continuous disclosure obligations at law and under the listing rules of the Australian Securities Exchange, the Company disclaims any obligation to update or revise any forward looking statements. The factors that may affect the Company’s future performance include, among others: changes in economic conditions, changes in the legal and regulatory regimes in which the Company operates, litigation or government investigations, decisions by regulatory authorities, changes in behaviour of major customers, suppliers and competitors, interruptions to manufacturing or distribution, the success of research and development activities and research collaborations and the Company’s ability to protect its intellectual property. Other ● A glossary of industry terminology is contained in the Mayne Pharma Annual Report which can be accessed at maynepharma.com/investor-relations/results-reports and product descriptions are detailed at maynepharma.com/us-products and maynepharma.com/au-products. ● DORYX®, FABIOR® and RHOFADE® are trademarks of Mayne Pharma. ANNOVERA®, BIJUVA®, EPSOLAY®, IMVEXXY®, NEXTSTELLIS®, TWYNEO® and WYNZORA® are trademarks of third parties. 3 International Dermatology A diversified portfolio of branded specialty and generic dermatology medicines including recently acquired products. Strategy to drive access and lower patient acquisition costs across rosacea, acne, psoriasis and atopic dermatitis. Strong focus on channel Disintermediation. Launch of DistributeRx in March 2026. Share price (ASX:MYX) $2.60 GICS Industry Group Code (Pharmaceuticals) 35202010 Shares on Issue 81.2 million Market Capitalisation $211.1 million FY26 Sales (Unaudited) $383.7 million FY25 Underlying EBITDA (Unaudited) $31.7 million Cash & Marketable Securities (30 June 2026) $80.0 million Top 20 Shareholders 59.6% Substantial Shareholders Funicular Funds LP (9.9%) Mr Bruce Mathieson (6.5%) Rubric Capital Management LP (5.4%) Trium Capital LLP (5.0%) Analyst Coverage Madeleine Williams: Canaccord Genuity Andrew Goodsall: MST Marquee Snapshot Corporate Summary1,2 1. Share price data, Top 20 shareholders as at 30 July 2026 2. Financial data per Mayne Pharma 2025 Annual Report, FY25 / 1H FY26 / 4Q FY26 results (unaudited) • Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel pharmaceuticals, offering patients better, safe and more accessible medicines • Mayne Pharma has a 40-year track record of innovation and success in developing new oral drug delivery systems. These technologies have been successfully commercialised in numerous products that continue to be marketed around the world Our Focus Segments Women’s Health A specialty branded portfolio with significant patent coverage focused on improving access and adherence in contraception and menopause care through targeted prescriber engagement and patient support. US Focus. Australian-based manufacturer (Salisbury, South Australia) with sales of branded and generic pharmaceutical products to customers and partners globally (ex-US) and the provision of contract development and manufacturing services to third party customers. Improving patient access to life-enhancing medications 4 Mayne Pharma in 2026 Branded Product Sales Now Represent a Significant Proportion (%) of Mayne Pharma’s Net Sales, Driving Margin Expansion 1. Unaudited financial information FY24 FY25 FY26 68% Branded │ 32% Generic 56% Gross Margin 79% Branded │ 21% Generic 61% Gross Margin 83% Branded │ 17% Generic 65% Gross Margin 500 bps 400 bps 68% 83% 79% 32% 21% 17% 5 A$174.3, 46% A$138.7, 36% A$70.7, 18% FY26 (Unaudited) Snapshot – Segments $107.3m FY26 Total Direct Contribution A$57.9, 54% A$44.6, 42% A$4.8, 4% Women’s Health FY26 Segment Contribution (A$m, % of total) Dermatology/DistributeRx International FY26 Revenue Contribution (A$m, % of total) 6 Global Headcount & Sales Force Global footprint Australia 244 18% Employees FY26 sales mix United States 223 82% Employees FY26 sales mix T O TA L H E A D C O U N T 1 467 Employees 1. As at 31 December 2025 Salisbury, South Australia Lexington, KY | Raleigh, NC Women’s Health sales representation of 90 persons DistributeRx sales representation of 23 persons Mayne Pharma International products manufactured from Salisbury are sold across international markets (ex-US) inc. Canada, Europe, Asia, Australia and NZ 7 US Indication Deal Structure and Terms Women’s Health Global footprint Branded Products Last Patent Expiry1 2043 2039 20342 2032 1. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations 2. Paragraph IV challenges for IMVEXXY brought by Sun Pharma and Teva. 3. Cumulative net sales of US$2.25 billion 4. The 10% royalty is deducted from Net Sales of ANNOVERA prior to the application of the 8% royalty payable to TXMD An Exclusively Licensed Portfolio for the US Market; manufacturing via third parties 8% Net Sales on all TXMD Licensed Products (ANNOVERA, IMVEXXY, BIJUVA) Royalties 10% Net Sales to Population Council (ANNOVERA)4 Pop. Council: US$40.0m (cumulative sales of US$400m: ANNOVERA) Pop. Council: US$40.0m (cumulative sales of US$1.0bn: ANNOVERA) TXMD: US$100m in net revenue (US$5m milestone payment) TXMD: US$200m in net revenue (US$10m milestone payment) TXMD: US$300m in net revenue (US$15m milestone payment) Variable COGS payment to Gedeon Richter (in gross margin) Dependent on forward sales of NEXTSTELLIS (no guidance provided) Licensor: TherapeuticsMD (TXMD) • January 2023 • Cash consideration to TXMD of US$140m and a US$13.1m payment for acquired NWC Licensor: Mithra (Gedeon Richter) • October 2019 • US$11m cash + equity upfront + up to US$295m in contingent payments3 Milestones Royalties Milestones Menopause Menopause Contraception Contraception 8 Women’s Health: the Rise of Menopause Global footprint Key Drivers 107 137 169 177 168 183 180 80 100 120 140 160 180 200 2HFY23 1HFY24 2HFY24 1HFY25 2HFY25 1HFY26 2HFY26 38 45 53 61 67 77 84 - 10 20 30 40 50 60 70 80 90 2HFY23 1HFY24 2HFY24 1HFY25 2HFY25 1HFY26 2HFY26 FY26 TRx +26% on pcp Net Sales: US$15.0m FY26 TRx +6% on pcp Net Sales: US$29.3m • Regulatory de-risking of the category: the FDA black boxed-warning removal for certain hormone replacement therapies (HRTs) in Nov 2025 (BIJUVA) • Demographic tailwind: A large, sustained cohort is moving into peri- and post- menopause representing 75m women now in the United States (+1.3m annually) • Celebrity-led destigmatisation: converting awareness into clinical demand • Expanding payer coverage: lowering the affordability barrier with US States actively seeking to improve access • Large market growth: menopause market is expected to grow from ~US$10B– 15B market in 2026 to ~US$15B–25B in 20301 FY26 Penetration of Category1: ~1% FY26 Penetration of Category1: ~2% Total Prescriptions (TRx) Total Prescriptions (TRx) 1. iQVIA data as at 30 June 2026 9 Dermatology Products Global footprint A portfolio of branded and generics Dermatology Last Patent Expiry 20351 2030 2039 2034 2041 2041 1. RHOFADE generic launch in July 2026 Branded Portfolio 25 Generics, Authorised Generics Products 31 Total Mayne Pharma Dermatology Products 6 Branded Products 10 Global footprint 100% Mayne Pharma owned subsidiary with a portfolio of branded and generics, both Mayne Pharma owned and Via Third Parties 1. As at 30 July 2026 2. Formal contracts with third party manufacturers in negotiation or recently signed (Resilia Pharma. ASX release 1 June 2026) 208 Other Non-Mayne Products sold via DistributeRx Channel1 31 14 + Additional Pipeline Products2 1 Contracted (1 Manufacturer); 13 in Pipeline (7 New Manufacturers) 239 Total Products Mayne Pharma Dermatology Products1 11 Mayne Pharma Disintermediation DistributeRx is Mayne Pharma's direct-to-patient distribution platform with Adelaide Apothecary serving as Mayne Pharma’s licensed pharmacy arm driving cash pay fulfilment of patient prescriptions as part of the Company’s overall disintermediation strategy. DistributeRx launched operations in March 2026. Total Investment at launch US$0.5m Disintermediation: Involves removing the intermediaries (wholesalers or others) between the manufacturer (Mayne Pharma) and the patient 60% Non-Wholesale volumes in FY261 1. As a % percentage of total US Women’s Health and Dermatology product volumes Unfilled Prescriptions High copays and complex prior authorizations cause patients to abandon prescriptions at the pharmacy counter Lost Profit Margin Rebates, DIR fees, and intermediary margins erode manufacturer profitability across the distribution chain Formulary Exclusions PBM restrictions limit formulary access, reducing branded product availability and patient choice Expanding Cash Market Patients increasingly bypass insurance, seeking lower-cost alternatives outside traditional channels Pharmacy Losses DIR clawbacks and below-cost reimbursement drive negative margins on branded dispensing The complexity of the US pharmacy distribution system creates barriers that impact manufacturers, pharmacies, and patients Cycle of inefficiency and waste 12 The US Pharmacy Distribution and Reimbursement System for Patient-Administered, Outpatient Brand-Name Drugs GPO= group purchasing organization; PSOA= pharmacy services administrative organization; DIR= direct and indirect remuneration; PBM= pharmacy benefit manager Source: Drug Channel’s Institute research. Chart illustrates flow for Patient-Administered, Outpatient Drugs. Please note that this chart is illustrative. It is not intended to be a complete representation of every type of product movement, financial flow, or contractual relationship in the marketplace. Product movement Financial flow Contract relationship • The path from manufacturer to patient is complex — and that complexity has real consequences. • Inefficient distribution, unpredictable pricing, and significant intermediary involvement create barriers at every step of the journey for manufacturers, clinicians, and patients alike. The Problem Manufacturer GPO Services contract Patient Third-party payer/ Health Plan Wholesale % Pass through of rebates and fees Reimbursement to PBM (including any network spread) PSAO Negotiation Services and data fees (specialty) Copayment or insurance Pharmacy Network participation Prescription Reimbursement Services agreement Rebates (DIR) & Fees Participation Participation Prime vendor agreement Pharmacy payment for product DIR Product shipment Product shipment Wholesaler payment for product Formulary agreement Dispense prescription Insurance premiums 13 Mayne Pharma Model to Support Efficiency & Profitability Manufacturers Pharmacy Patients The Mayne Pharma approach is simple, efficient, and direct: • Simple — Fewer intermediaries mean clearer pricing for clinicians and more consistent access to therapy for patients. • Efficient — Streamlined distribution reduces friction across the product lifecycle, improving gross-to-net results for manufacturers. • Direct — Medications reach patients faster, with transparent pricing and fewer delays in care. The Solution 14 DistributeRx partners with manufacturers, providers, and pharmacies to improve patient access and offer predictable prices PRESCRIPTION ACCESS MADE SIMPLE 1. Precedence Research • ePharmacy size ~US$252 billion by 2030 (CAGR 17%)1 driven by rising consumer adoption of digital pharmacy and home delivery • Initial DistributeRx launch exceeded expectations, delivering very strong growth in March versus forecast, prior month and pcp • Strong demand profile: May 2026 announced major expansion of Adelaide Apothecary (MYX cash pay pharmacy) in Lexington, KY • Up to 2.5m Rx per annum capacity, US$4m CAPEX across two phases for equipment and automation capability +87% Q4 FY26 Rx growth versus the pcp ~25,000 Total Rx Q4 FY26 ~5,000 New prescribers added since launch 15 DistributeRx Solution Versus Competitive Set FEATURE DISTRIBUTERx NATIONAL HUBS (BLINKRx, PHILRx) AMAZON PHARMACY MARK CUBAN COST + DRUGS INDEPENDENT PHARMACIES Prescription Fulfillment Home Delivery LIMITED Prior Authorization Support PARTIAL PARTIAL Wholly Owned Cash Pharmacy Price Transparency PARTIAL Dermatology Expertise Insurance Independence PARTIAL National Scalability 16 Recent M&A Activity in Women’s Health & Dermatology Markets Women’s Health Dermatology US$11.75B Sun Pharma → Organon Apr 2026 | Largest pharma deal of 2026. Creates top-3 global women’s health player with 70+ products across 140 countries. Also enters biosimilars as 7th largest global player. US$18.3B Blackstone/TPG → Hologic Oct 2025 (closed Apr 2026) | Take-private of global women’s health medtech leader. 46% premium. Includes breast health, diagnostics, and gynecological surgical products. Up to US$1.2B Organon → Dermavant Oct 2024 | Adds VTAMA (tapinarof) for plaque psoriasis and atopic dermatitis. US$175m upfront + US$75m regulatory + US$950m commercial milestones. US$1.3B J&J → Yellow Jersey Therapeutics May 2024 | Atopic dermatitis pipeline acquisition. Adds novel biologic candidates to J&J’s immunology portfolio. Women’s Health and Dermatology are among the most active M&A sectors in pharma — validating the strategic value of specialty portfolios in these therapeutic areas Sources: Company announcements, Fierce Pharma, DealForma, PitchBook. Deal values as announced; may include contingent payments. 17 Future Growth Drivers Women’s Health Dermatology • Drive Market Penetration – increase low single digit market share + solid market growth • Portfolio economics – long-dated patent life to protect value, support pricing power, and sustain investment • Commercial execution – upgraded marketing, optimised field-force effectiveness, tighter targeting of high-value prescribers • Improving Access – payer contracting and patient access programs to reduce pharmacy friction and drive higher fill rates International • Scale disintermediation – specialty pharmacy ecosystem to reduce friction and lift direct contribution as mix improves: DistributeRx • Expand portfolio – capital-efficient BD and targeted acquisitions of new FDA-approved brands to broaden addressable segments • Drive Rx growth – stronger commercial execution, sales force upgrades, and refreshed marketing to accelerate demand • Margin focus – through product mix and channel shift towards higher-value brands and more favourable channel economics • Salisbury capacity – post-upgrade enabling higher output, better service levels, and improved DIFOT to support export growth • NEXTSTELLIS PBS – listing tailwind driving Australian Rx growth as affordability and access improves • Operating leverage – unlock value from significant infrastructure investment and improved facility utilisation • Expanded partnerships – international supply agreements to grow exports and increase third-party volume through the network You deserve tomorrow. For further information contact: Dr Tom Duthy Investor Relations +61 402 493 727 ir@maynepharma.com To register for an email alert service to receive Mayne Pharma announcements released to the Australian Securities Exchange (ASX) please visit https://www.maynepharma.com/investor-relations/email-alerts/ Follow us on LinkedIn